^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET inhibitor

    Related drugs:
    1d
    Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing. (PubMed, Nat Biotechnol)
    We experimentally validated several actionable findings, including tepotinib to target the IRAK1/4-cholesterol pathway in glioblastoma, brigatinib to target the MARK2/3-Hippo pathway in pancreatic cancer and gilteritinib to overcome MET mutation-driven drug resistance and metastasis. To facilitate exploration of our data, we provide KIRHub, a web-based tool that allows identification of existing inhibitors of wild-type and mutated kinases to guide precision oncology.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR (Fibroblast Growth Factor Receptor) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1) • MARK2 (Microtubule Affinity Regulating Kinase 2)
    |
    MET mutation
    |
    Xospata (gilteritinib) • Alunbrig (brigatinib) • Tepmetko (tepotinib)
    3d
    CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer. (PubMed, J Clin Oncol)
    Savolitinib plus durvalumab shows OS in MET-driven PRC, supporting the ongoing SAMETA RIII trial (ClinicalTrials.gov identifier: NCT05043090). ctDNA may be a useful predictive biomarker.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    MET mutation
    |
    FoundationOne® CDx
    |
    Imfinzi (durvalumab) • Orpathys (savolitinib)
    9d
    swalloWTail: A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Feb 2026 --> May 2026
    Trial primary completion date
    |
    docetaxel • Rybrevant (amivantamab-vmjw)
    9d
    PALOMA: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (clinicaltrials.gov)
    P1, N=158, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2026 --> Apr 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
    15d
    CSB-C23-002: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars (clinicaltrials.gov)
    P1, N=20, Recruiting, Claris Biotherapeutics, Inc. | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    15d
    CSB-C23-001: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency (clinicaltrials.gov)
    P1, N=65, Recruiting, Claris Biotherapeutics, Inc. | Trial completion date: May 2026 --> Dec 2027 | Trial primary completion date: Nov 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    16d
    SAFFRON: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (clinicaltrials.gov)
    P3, N=345, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • MET overexpression
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)
    17d
    Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study. (PubMed, Lancet Reg Health West Pac)
    Savolitinib demonstrated robust and durable efficacy in patients with METex14-mutated, locally advanced NSCLC with manageable safety, supporting savolitinib as a treatment option in this disease setting. HUTCHMED, AstraZeneca.
    P3 data • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation • MET mutation
    |
    Orpathys (savolitinib)
    18d
    Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer. (PubMed, Lung Cancer Manag)
    The incremental cost-effectiveness ratio (ICER) of Capmatinib treatment vs. Tepotinib treatment was calculated at 60,977.28 USD/QALY. Tepotinib was not cost-effective compared to Capmatinib as the second-line treatment for advanced or metastatic NSCLC patients with MET exon 14 skipping mutations in China.
    Review • Journal • HEOR • Cost-effectiveness
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation • MET mutation
    |
    Tepmetko (tepotinib) • Tabrecta (capmatinib)
    19d
    KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma. (PubMed, Eur Urol)
    CALYPSO (NCT02819596) was a prospective, multi-arm trial that evaluated durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC. Also, an increase in KIM-1 during therapy was linked to worse progression-free survival (HR 1.7; 95% CI, 1.13-2.58; p = 0.01) and OS (HR 1.95; 95% CI, 1.23-3.08; p = 0.004) in ccRCC. This exploratory analysis supports the utility of KIM-1 in advanced ccRCC and pRCC.
    Journal • PD(L)-1 Biomarker
    |
    KIM1 (Kidney injury molecule 1)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Orpathys (savolitinib)
    19d
    DO2.22.01: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours (clinicaltrials.gov)
    P1, N=55, Recruiting, DeuterOncology | N=25 --> 55 | Trial completion date: Dec 2026 --> Sep 2028 | Trial primary completion date: Dec 2025 --> Sep 2027 | Active, not recruiting --> Recruiting
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    DO-2